myTomorrows partners with Pancreatic Cancer Europe to streamline clinical trials

Pancreatic cancer is the fourth leading cause of cancer deaths, with a life expectancy of only 6-12 months at time of diagnosis and a 5-year survival rate of only 10%. The many challenges associated with pancreatic cancer include a lack of awareness about the disease among the public, difficulty in diagnosis, which is late, treatment resistance to chemo and radiation therapy, poor survival rates, and limited treatments. Therefore, it is crucial for patients to be as accurately and thoroughly informed as possible about their treatment options – especially clinical trials, which are often difficult to find, understand, and navigate.

For pancreatic cancer patients, their loved ones, and the Health Care Professionals (HPCs) who treat them, the partnership will ease the process of identifying and understanding the existing clinical trial options. In doing so, it will enable them to make the best possible decisions about their treatment, with myTomorrows’ expert patient navigators demystifying the complexities of clinical trials and supporting patients and their families throughout the process. A new clinical trial search tool, which will be featured on the Pancreatic Cancer Europe website, will make it even easier and quicker to search for relevant treatment options across myTomorrows’ vast database of ongoing clinical trials worldwide.

“We are very excited to be partnering with Pancreatic Cancer Europe, an organisation that works tirelessly to raise awareness of pancreatic cancer, promote advancements in treatments, and empower European member organisations to better address the relevant issues regarding the disease,” said Dr. Michel van Harten, CEO of myTomorrows. “Collaborating with leading patient advocacy groups like PCE helps us extend our reach to more patients in need and empower them to navigate their treatment journeys with more confidence and knowledge, while enabling pharmaceutical companies to expand access throughout the drug development cycle.”

“This new partnership is an important step in the persistent fight against pancreatic cancer,” said Prof. Alfredo Carrato, Chair of Pancreatic Cancer Europe. “The innovative myTomorrows platform will support patients suffering from pancreatic cancer, their caregivers and their treating physicians by significantly easing the process of accessing and navigating clinical trials, another opportunity for them, enabling a more informed and proactive approach to treatment of this devastating disease.”